OMNIVIUM PHARMS
PharmaOMNIVIUM PHARMS is a pharmaceutical company focused on Cardiovascular, Metabolic. Key products include NUMBRINO.
OMNIVIUM PHARMS's Key Drugs
OMNIVIUM PHARMS's core commercial portfolio centers on NUMBRINO, spanning Cardiovascular and Metabolic — its most strategically important drugs approved in the last 15 years.
OMNIVIUM PHARMS's Recent FDA Approvals
New NDA/BLA approvals for OMNIVIUM PHARMS over the last two years — novel drugs only, excluding generics and label supplements.
OMNIVIUM PHARMS's Therapeutic Areas
OMNIVIUM PHARMS's approved drugs and pipeline span 2 therapeutic areas, led by Cardiovascular and Metabolic, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
OMNIVIUM PHARMS's Top Competitors
OMNIVIUM PHARMS's closest competitors by therapeutic-area and drug-target overlap include Merck, Baxter, and Sanofi. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
OMNIVIUM PHARMS Pipeline Snapshot
Active clinical trials for OMNIVIUM PHARMS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • NUMBRINO leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 1993-06-30
- Latest
- 2026-01-23
- Applications
- 7